Radiotherapy Treatments for Neoplasms of the Limbs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-02-22

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this observational study patients treated at European Institute of Oncology with radiotherapy to limbs will be included

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Optimization of Radiotherapy in Treatment of Painful Bone Metastasis

NCT00610272

Pain Bone Metastasis

COMPLETED PHASE3

Radiotherapy Treatments for Neoplasms in the Head and Neck Region

NCT06335342

Head and Neck Neoplasms

RECRUITING

Radiotherapy Treatments for the Treatment of Thoracic District Tumors

NCT06335290

Thoracic Neoplasms

RECRUITING

Radiotherapy Treatments for Neoplasms in the Abdominal-pelvic Region

NCT06335238

Abdominal Cancer Pelvic Cancer

RECRUITING

Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients With KPS

NCT02376322

Bone Metastases

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Approximately 60% of patients with neoplasms receive radiotherapy as part of their oncological treatment. Various primary tumors as well as metastases of various origins can be localized in the upper or lower limbs. Patients with such neoplastic localizations will therefore receive radiotherapy treatment possibly associated with other systemic or surgical treatments.

Treatment choice is usually established following multidisciplinary discussions, based on disease characteristics and stage, concurrent pathologies and pharmacological treatments, patient preferences, and functional aspects.

Data collection related to radiotherapy plays a crucial role in understanding various clinical aspects of the treatment itself. The availability of data from an increasing number of patients will allow the identification of clinical situations or technical parameters of radiotherapy correlated with treatment tolerance and effectiveness, aiming to identify the best treatment for these oncological pathologies.

This project aims to collect data related to radiotherapy treatments for primary or secondary neoplasms localized in the upper or lower limbs for scientific dissemination with the goal of establishing the basis for evaluating achieved results over time, and deriving from these elements useful for guiding the most effective treatment strategies and appropriate operational protocols.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bone Neoplasms Bone Metastases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Radiotherapy to limbs

Collection of data of patients receiving RT to limbs

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients treated with radiotherapy for curative, palliative, neo-adjuvant, and adjuvant purposes in the upper and lower limbs for:

Primary bone tumors, Primary soft tissue tumors, Primary tumors of the cardio-circulatory system, Primary tumors of the lymphatic system, Primary tumors of the nervous system and skin, Secondary metastases from various origins localized in that district.
2. Signed informed consent